PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
Estudo PRIMA: niraparib demonstra benefício na PFS a longo prazo no tratamento de 1.ª linha do cancro do ovário
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
CME; Niraparib, Olaparib, bevacizumab, PRIMA trial, PAOLO-1
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Niraparib in Patients With Newly Diagnosed Advanced Ovarian BRCAm Cancer: A Post Hoc Analysis of the PRIMA/ENGOT-OV26/GOG-3012 T
Efficacy | ZEJULA (niraparib) for HCPs
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Treatment and Maintenance Therapy in Advanced Ovarian Cancer | VuMedi
Zejula (niraparib) com resultados positivos como terapêutica de primeira linha | Netfarma
Efficacy of niraparib in the PRIMA trial | Download Scientific Diagram
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Treatment Considerations With Niraparib
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
Use of First-Line PARP Inhibitors in Ovarian Cancer | Published in healthbook TIMES Oncology Hematology
Pivotal Trials in the Realm of Ovarian Cancer
